AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05118633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device and app system designed for participant to self-administer Habit Reversal Training and Stimulus Control
Description: Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training and Stimulus Control. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania, as well as receive stimulus control reminders.
Study NCT05118633 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reminder bracelet and journaling app control condition
Description: Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull. They will also be instructed to journal in an app on their phone several times per day.
Study NCT06387212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 35 kDa hyaluronan fragment HA35 injection
Description: First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).
Study NCT05525403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Extension Exercise
Description: Participants will be seated in a Steel Flex machine with weight equal to 50% of their 1 repetition maximum added to the machine. Participants will extend the dominant knee until the assigned fatigue level.
Study NCT05525403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quiet Rest
Description: Participants will sit quietly for two minutes, three times.
Study NCT06218940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY1272
Description: Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
Study NCT05965830 — intervention group
Intervention type: DEVICE
Intervention: Diaphragm ultrasound
Description: A single, simultaneous assessment of the diaphragm muscle functioning through dEMG and dUS at the time of spontaneous breathing.
Study NCT04987125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyspnea Neuroscience education
Description: Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors.~The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
Study NCT04987125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
Study NCT05200858 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS - low-dose
Description: Subjects will receive a placebo TENS device (delivers 10% of the dose) to wear for 3-5 hours per day.
Study NCT04893655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine Hydrochloride
Description: dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
Study NCT05865509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escape room
Description: Students were given training on stress response using the escape room method.
Study NCT05865509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Storytelling
Description: Students were given training on stress response using the storytelling method.
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400mg, qd, po, day 1-21
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg, day 1
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6 mg/kg, day 1
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 420 mg, day 1
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2, day 1
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100 mg/m2, day 1
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90mg/m2, day 1
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90mg/m2, day 1
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, day 1
Study NCT04717531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, day 1
Study NCT06651359 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Surveys for Quality of Life
Description: This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).
Study NCT06651359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys for Quality of Life
Description: This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).
Study NCT06651359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys and mHealth App access
Description: This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL). Additionally, they will have a brief initial study visit, in-person or virtually, to review the app use. This arm of participants will use the mobile application at home for 12 months. During the first 12 weeks, the application will send daily surveys about symptoms, dietary and physical activities, weekly surveys about their mood, and an assessment of their overall QoL every 3 months. The app will provide tailored educational content, including short readings, videos, and audio recordings, to help users learn more about managing symptoms and improving their functioning. After 12 months of app use, an interview will be conducted to gather feedback about their experiences with the app. The information collected from these interviews will be analyzed to further enhance and improve the app's functionality.
Study NCT05610319 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Faricimab
Description: Faricimab will be administered via intravitreal injection.
Study NCT05610319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered via intravitreal injection.
Study NCT06606405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: scapular dyskinesis test
Description: Scapular dyskinesia in athletes will be visually evaluated. It will be considered present if, during 3 out of 5 arm elevation attempts, any of the following are observed: prominence of the medial or upper scapular border, lower scapular angle, excessive clavicular elevation, or rapid downward rotation of the scapula. After the tester demonstrates the required movements, the athletes will practice the movement. The test will begin with the arms at the sides of the body, elbows straight, and shoulders in neutral rotation. Two testers will observe from behind and video record the movements. Participants will be instructed to raise their arms as high as possible simultaneously, using the \&amp;#39;thumbs up\&amp;#39; position, and to maintain this position for 3 seconds before lowering their arms for another 3 seconds. Athletes will perform the arm elevation with a dumbbell weight calculated as 1.4% of their body weight (Kamonseki, Haik, Ribeiro, Almeida, \&amp;amp; Camargo, 2023).
Study NCT06760520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab (SMT112 or AK112) Injection
Description: Eligible subjects will receive short-course radiotherapy (SCRT), 25Gy/5f/1 week. 1-2 weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 850-1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Study NCT06247774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Participation in a 12-week cardiac rehabilitation program
Study NCT06247774 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Participants will receive regular phone calls in place of cardiac rehabilitation visits
Study NCT05157581 — intervention group
Intervention type: DEVICE
Intervention: Extracorporeal photopheresis (ECP)
Description: Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
Study NCT05157581 — intervention group
Intervention type: DRUG
Intervention: Methoxsalen Injection
Description: Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
Study NCT06115330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press Needle Acupuncture
Description: Ear acupuncture using Pyonex press needles were installed with a diameter of 0.17mm, 0.9mm deep. The needles were retained for three days and stimulated at the installation site of the patch needle by means of pressure on the acupuncture point ears that have been attached needles on both sides, 1 minute at each point, four times a day, for 3 consecutive days and the patch was removed on the 3rd day
Study NCT05323617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Administered as a subcutaneous injection.
Study NCT05323617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: Horse or rabbit antithymocyte globulin administered as an intravenous infusion.
Study NCT05323617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Administered orally.
Study NCT06018792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular Culture
Description: PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.
Study NCT05213195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKG2D CAR-NK
Description: NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.
Study NCT04676425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Administered at a dose of 4 mg via oral tablet
Study NCT06398483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical fixation of acute bony mallet finger
Description: surgical fixation of acute bony mallet finger by micro plate will be performed under either Infraclavicular nerve blockage or digital block will be performed in all patients .fracture fragment will be reduced, The legs of the plate will be embedded in the terminal tendon to grasp the fragment. The plate will be fixed to the distal phalanx with a 1.3-mm screw.~surgical fixation of acute bony mallet finger by blocking K.wire will be performed under either infraclavicular nerve block or digital block. The injury will be surgically intervened with an extensor blocking k.wire. the distal phalanx was extended to maximum flexion and (K.wire) will be placed in the cephalic direction through the terminal band at an angle of 45 degrees to the mid-phalanx. Reduction of the fracture fragment will be achieved by bringing the distal phalanx to extension . the DIP will be transfixed with a second K-wire
Study NCT05064787 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital Health Coaching
Description: The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
Study NCT06286124 — intervention group
Intervention type: PROCEDURE
Intervention: Hybrid Surgery
Description: Hybrid incisional hernia repair, as described by Van den Dop et al. (2021)
Study NCT05083195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Telerehabilitation
Description: Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
Study NCT05083195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Brochure
Description: Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
Study NCT05616364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Dexmedetomidine intravenous
Study NCT05616364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramadol intravenous
Study NCT05423535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: test group: collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland)
Description: Following tooth extraction and wound debridement, the alveolar socket was filled with collagen-enriched deproteinized bovine bone mineral (C-DBBM, Bio-Oss Collagen® 100 mg or 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) up to the level of the oral bone crest. Subsequently, a collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland) or gelatin spons (Spongostan Dental® 1x1x1 cm, Ethicon, Johnson \& Johnson, New Brunswick, VS) was sutured on top with 4 to 6 single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to protect the underlying C-DBBM.
Study NCT06014229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
Study NCT06395181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Food Plant-Based Diet
Description: A whole food, plant-based diet focuses on whole foods that are not processed. The diet places an emphasis on plant foods that are naturally lower in fat and includes eating a variety of plant foods (fruits, vegetables, beans and legumes, whole grains, nuts and seeds, spices and herbs).
Study NCT06200337 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle acupuncture
Description: All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.
Study NCT06096870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)
Study NCT06096870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: M9241 at 12.0 microgram/kg by subcutaneous injection (every 28 days)
Study NCT05423535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test group: collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland)
Description: Following tooth extraction and wound debridement, the alveolar socket was filled with collagen-enriched deproteinized bovine bone mineral (C-DBBM, Bio-Oss Collagen® 100 mg or 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) up to the level of the oral bone crest. Subsequently, a collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland) or gelatin spons (Spongostan Dental® 1x1x1 cm, Ethicon, Johnson \& Johnson, New Brunswick, VS) was sutured on top with 4 to 6 single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to protect the underlying C-DBBM.
Study NCT06334328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based mindful movement therapy
Description: VR-MMT combines VR games, multisensory and cognitive stimulation, hand-eye and full body coordination, creative processes, expressive movement, mindfulness practice, and social connectedness.
Study NCT06329726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examinations and clinical scales administration
Description: Psychometric assessment of cognitive and behavioral outcomes
Study NCT05742425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Combined With FOLFIRI and Bevacizumab
Description: For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
Study NCT04559438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotary Neoniti GPS file
Description: Glide path creation will be achieved using Neoniti GPS file (15/.03). The file will be introduced passively inside the canal, in continuous rotation at a constant speed between 300 and 500 rpm and torque of 1.5 N.
Study NCT04559438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual stainless steel K-files
Description: Glide path preparation will be done by hand instrumentation using K-files #10 and 15.
Study NCT05237102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid shunt
Description: The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）
Study NCT06483802 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ASP2016
Description: Intravenous (IV) infusion
Study NCT06483802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral
Study NCT05961800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cutaneous Probe
Description: A computer-controlled probe delivers temperatures to the skin to measure pain, offset analgesia and onset hyperalgesia.
Study NCT05237102 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cerebrospinal fluid shunt
Description: The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）
Study NCT05961800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
Study NCT05961800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Tasks
Description: Quantitative Sensory Testing (QST) and computer tasks are used to measure changes in pain intensity.